| 一般的な頻出語を「文章内」のリストから除外しています |
| 2語前 |
1語前 |
|
1語後 |
2語後 |
|
文章内 |
| with |
37 |
has |
155 |
|
to |
235 |
be |
205 |
|
patients |
93 |
| has |
33 |
have |
65 |
|
that |
89 |
in |
61 |
|
biopsy |
67 |
| and |
29 |
biopsy |
57 |
|
the |
52 |
for |
53 |
|
study |
64 |
| of |
20 |
may |
44 |
|
useful |
44 |
to |
49 |
|
useful |
63 |
| have |
17 |
we |
39 |
|
challenging |
36 |
the |
38 |
|
effective |
62 |
| the |
17 |
been |
38 |
|
difficult |
31 |
and |
17 |
|
cell |
56 |
| that |
16 |
to |
33 |
|
a |
25 |
a |
13 |
|
however |
55 |
| it |
16 |
was |
31 |
|
by |
18 |
have |
13 |
|
challenging |
55 |
| this |
12 |
and |
28 |
|
effective |
17 |
of |
13 |
|
cells |
52 |
| which |
11 |
with |
22 |
|
acute |
15 |
rejection |
11 |
|
clinical |
52 |
| we |
10 |
could |
13 |
|
its |
13 |
as |
11 |
|
disease |
47 |
| is |
9 |
also |
12 |
|
in |
11 |
effective |
9 |
|
method |
44 |
| not |
7 |
are |
12 |
|
elusive |
11 |
efficacy |
7 |
|
high |
44 |
| to |
7 |
of |
10 |
|
successful |
10 |
due |
7 |
|
based |
44 |
| was |
6 |
a |
10 |
|
valuable |
10 |
this |
7 |
|
treatment |
42 |
| been |
6 |
is |
10 |
|
probable |
9 |
useful |
6 |
|
using |
41 |
| patients |
6 |
culture |
9 |
|
beneficial |
8 |
or |
6 |
|
difficult |
40 |
| approaches |
5 |
not |
9 |
|
their |
8 |
with |
6 |
|
studies |
38 |
| they |
5 |
will |
9 |
|
nafld |
7 |
challenging |
5 |
|
data |
37 |
| studies |
5 |
might |
8 |
|
more |
7 |
presence |
5 |
|
n |
37 |
| approach |
5 |
no |
7 |
|
this |
7 |
potential |
5 |
|
both |
35 |
| method |
5 |
results |
7 |
|
as |
6 |
it |
5 |
|
analysis |
35 |
| developed |
5 |
should |
7 |
|
clinical |
6 |
were |
5 |
|
specific |
35 |
| were |
5 |
were |
6 |
|
safe |
5 |
utility |
4 |
|
two |
33 |
| our |
5 |
which |
6 |
|
and |
5 |
effectiveness |
4 |
|
therapeutic |
33 |
| for |
4 |
method |
6 |
|
highly |
5 |
usefulness |
4 |
|
cancer |
32 |
| these |
4 |
further |
6 |
|
recurrence |
4 |
because |
3 |
|
human |
32 |
| findings |
4 |
can |
5 |
|
therapeutic |
4 |
powerful |
3 |
|
approach |
32 |
| are |
4 |
thus |
5 |
|
an |
4 |
therapies |
3 |
|
tool |
31 |
| thus |
3 |
that |
5 |
|
particularly |
4 |
who |
3 |
|
new |
31 |
| but |
3 |
pathologically |
5 |
|
critical |
4 |
we |
3 |
|
different |
31 |
| assay |
3 |
as |
5 |
|
less |
4 |
are |
3 |
|
risk |
31 |
| pathways |
3 |
approach |
5 |
|
nash |
4 |
non |
3 |
|
used |
30 |
| may |
3 |
far |
4 |
|
powerful |
3 |
existence |
3 |
|
potential |
30 |
| proposed |
3 |
the |
4 |
|
extremely |
3 |
concept |
3 |
|
other |
29 |
| experiments |
3 |
already |
4 |
|
high |
3 |
disease |
3 |
|
years |
29 |
| theory |
3 |
but |
4 |
|
for |
3 |
but |
3 |
|
models |
28 |
| a |
3 |
only |
4 |
|
bkpyvan |
3 |
strategy |
3 |
|
h |
28 |
| in |
3 |
data |
4 |
|
efficacy |
3 |
2 |
2 |
|
molecular |
28 |
| needed |
3 |
this |
4 |
|
efficacious |
3 |
was |
2 |
|
acute |
27 |
| cells |
3 |
analysis |
4 |
|
helpful |
3 |
near |
2 |
|
results |
27 |
| 2 |
3 |
assay |
3 |
|
treatment |
3 |
active |
2 |
|
associated |
27 |
| if |
3 |
studies |
3 |
|
remarkably |
2 |
feasibility |
2 |
|
detection |
27 |
| cancer |
2 |
pathology |
3 |
|
clinically |
2 |
effects |
2 |
|
non |
27 |
| materials |
2 |
model |
3 |
|
promising |
2 |
use |
2 |
|
use |
27 |
| from |
2 |
surgically |
3 |
|
invaluable |
2 |
ability |
2 |
|
no |
27 |
| failure |
2 |
it |
3 |
|
data |
2 |
effectively |
2 |
|
model |
27 |
| had |
2 |
thereby |
3 |
|
vital |
2 |
applicability |
2 |
|
although |
26 |
| interaction |
2 |
samples |
3 |
|
fruitful |
2 |
stability |
2 |
|
highly |
26 |
| or |
2 |
recently |
3 |
|
essential |
2 |
they |
2 |
|
19 |
24 |
| methods |
2 |
histologically |
3 |
|
it |
2 |
has |
2 |
|
time |
24 |
| biosynthesis |
2 |
clinically |
3 |
|
sufficient |
2 |
over |
2 |
|
methods |
24 |
| platforms |
2 |
genetically |
3 |
|
or |
2 |
targets |
2 |
|
only |
24 |
| models |
2 |
cells |
2 |
|
treatments |
2 |
at |
2 |
|
g |
23 |
| so |
2 |
evm |
2 |
|
rejection |
2 |
treatment |
2 |
|
therapy |
23 |
| based |
2 |
rarely |
2 |
|
ineffective |
2 |
rejections |
2 |
|
due |
23 |
| years |
2 |
days |
2 |
|
rcc |
2 |
against |
2 |
|
into |
23 |
| order |
2 |
spectroscopy |
2 |
|
vehicle |
2 |
safety |
2 |
|
low |
22 |
| as |
2 |
therefore |
2 |
|
necessary |
2 |
despite |
2 |
|
single |
22 |
| behavior |
2 |
often |
2 |
|
active |
2 |
difficult |
2 |
|
range |
22 |
| yet |
2 |
then |
2 |
|
sepsis |
2 |
acute |
2 |
|
first |
22 |
| work |
2 |
study |
2 |
|
food |
2 |
sensitive |
2 |
|
s |
22 |
| however |
2 |
challenge |
2 |
|
suitable |
2 |
allergy |
2 |
|
t |
21 |
| diagnosis |
2 |
successfully |
2 |
|
pharmacological |
2 |
is |
2 |
|
materials |
21 |
| sporadic |
2 |
ultimately |
2 |
|
fertile |
2 |
during |
2 |
|
valuable |
21 |
| drugs |
2 |
reaction |
2 |
|
cases |
2 |
our |
2 |
|
cases |
21 |
| s |
2 |
experiments |
2 |
|
infection |
2 |
on |
2 |
|
role |
21 |
| effect |
2 |
polymers |
2 |
|
most |
2 |
water |
2 |
|
one |
21 |
| measures |
2 |
conditions |
2 |
|
drug |
2 |
t |
2 |
|
drug |
21 |
| humans |
2 |
previously |
2 |
|
gerd |
2 |
relevance |
2 |
|
function |
20 |
| review |
2 |
they |
2 |
|
very |
2 |
clinical |
2 |
|
target |
20 |
| infection |
2 |
histopathologically |
2 |
|
advantageous |
2 |
n |
2 |
|
effects |
20 |
| tested |
2 |
be |
2 |
|
problematic |
2 |
novel |
2 |
|
vivo |
20 |
| microbes |
2 |
for |
2 |
|
her2 |
2 |
naive |
2 |
|
ability |
20 |
| species |
2 |
experimentally |
2 |
|
reproducible |
2 |
by |
2 |
|
many |
20 |
| despite |
2 |
coating |
2 |
|
multiple |
2 |
many |
2 |
|
gene |
20 |
| 7 |
2 |
process |
2 |
|
superiority |
2 |
pulmonary |
2 |
|
efficient |
19 |
| techniques |
2 |
if |
2 |
|
protective |
2 |
system |
2 |
|
mechanisms |
19 |
| disease |
2 |
their |
2 |
|
midd |
2 |
key |
2 |
|
obtained |
19 |
| results |
2 |
algorithm |
2 |
|
melanoma |
1 |
ineffective |
1 |
|
functional |
19 |
| signaling |
2 |
printing |
1 |
|
aspiration |
1 |
pneumonia |
1 |
|
reaction |
19 |
| therapies |
2 |
ligands |
1 |
|
hf |
1 |
covid |
1 |
|
against |
19 |
| blood |
2 |
previous |
1 |
|
fatal |
1 |
study |
1 |
|
development |
19 |
| solution |
2 |
cooking |
1 |
|
disappointing |
1 |
yet |
1 |
|
p |
19 |
| proteins |
2 |
stage |
1 |
|
infectious |
1 |
precision |
1 |
|
over |
19 |
| technologies |
2 |
dehydration |
1 |
|
h |
1 |
valuable |
1 |
|
c |
19 |
| expression |
2 |
fraction |
1 |
|
antiviral |
1 |
endophthalmitis |
1 |
|
efficacy |
19 |
| also |
2 |
neuroimaging |
1 |
|
composting |
1 |
available |
1 |
|
through |
19 |
| only |
2 |
35 |
1 |
|
ich |
1 |
significantly |
1 |
|
properties |
19 |
| networks |
2 |
without |
1 |
|
positive |
1 |
provide |
1 |
|
number |
19 |
| imaging |
2 |
tqs |
1 |
|
impossible |
1 |
antibodies |
1 |
|
protein |
19 |
| analysis |
2 |
habitats |
1 |
|
experimentally |
1 |
susceptible |
1 |
|
compared |
18 |
| model |
2 |
substituent |
1 |
|
pe |
1 |
potent |
1 |
|
activity |
18 |
| tools |
2 |
materials |
1 |
|
ageing |
1 |
compensate |
1 |
|
during |
18 |
| peptides |
2 |
consistently |
1 |
|
services |
1 |
systemic |
1 |
|
patient |
18 |
| 3 |
2 |
acid |
1 |
|
false |
1 |
ce |
1 |
|
water |
18 |
| strategy |
2 |
autopsy |
1 |
|
biologic |
1 |
offer |
1 |
|
further |
18 |
| spectroscopy |
2 |
interest |
1 |
|
good |
1 |
vivo |
1 |
|
response |
18 |
| analytes |
2 |
disorder |
1 |
|
causality |
1 |
plasma |
1 |
|
understanding |
18 |
| study |
2 |
now |
1 |
|
selectable |
1 |
prevalent |
1 |
|
compounds |
18 |
| reactivity |
1 |
effect |
1 |
|
themselves |
1 |
take |
1 |
|
type |
18 |
| learning |
1 |
analyses |
1 |
|
lethal |
1 |
precise |
1 |
|
novel |
18 |
| simulant |
1 |
potential |
1 |
|
instrumental |
1 |
tumor |
1 |
|
research |
18 |
| 5 |
1 |
actions |
1 |
|
feasibility |
1 |
associated |
1 |
|
including |
18 |
| electrophile |
1 |
mathematically |
1 |
|
inconsistent |
1 |
visualize |
1 |
|
despite |
18 |
| be |
1 |
gas |
1 |
|
predictive |
1 |
plausibility |
1 |
|
small |
18 |
| 3d |
1 |
bph |
1 |
|
nmdar |
1 |
performance |
1 |
|
infection |
18 |
| 2020 |
1 |
antibodies |
1 |
|
gastroesophageal |
1 |
patients |
1 |
|
targeting |
17 |
| ether |
1 |
lactone |
1 |
|
prohibitive |
1 |
clearly |
1 |
|
overall |
17 |
| areas |
1 |
5 |
1 |
|
target |
1 |
computational |
1 |
|
well |
17 |
| antibiotics |
1 |
ftis |
1 |
|
causation |
1 |
refined |
1 |
|
process |
17 |
| concentrations |
1 |
suite |
1 |
|
reliable |
1 |
diagnostic |
1 |
|
strategy |
17 |
| exendin |
1 |
probable |
1 |
|
rate |
1 |
marker |
1 |
|
included |
17 |
| adaptation |
1 |
despite |
1 |
|
intermediate |
1 |
theory |
1 |
|
targets |
17 |
| simple |
1 |
biopsies |
1 |
|
possible |
1 |
repeatability |
1 |
|
rejection |
16 |
| immunotherapy |
1 |
muteins |
1 |
|
sb |
1 |
supporting |
1 |
|
experimental |
16 |
| before |
1 |
yet |
1 |
|
safety |
1 |
any |
1 |
|
therapies |
16 |
| photocatalyst |
1 |
protocols |
1 |
|
exceedingly |
1 |
terms |
1 |
|
powerful |
16 |
| current |
1 |
protocol |
1 |
|
crucial |
1 |
incorrectly |
1 |
|
complex |
16 |
| heterogeneity |
1 |
signature |
1 |
|
severe |
1 |
oral |
1 |
|
covid |
16 |
| prevention |
1 |
iaes |
1 |
|
both |
1 |
which |
1 |
|
performance |
16 |
| products |
1 |
nomogram |
1 |
|
well |
1 |
analysis |
1 |
|
cohort |
16 |
| application |
1 |
overexpression |
1 |
|
directly |
1 |
gangrenous |
1 |
|
receptor |
16 |
| 46 |
1 |
locus |
1 |
|
rehabilitative |
1 |
across |
1 |
|
reduction |
16 |
| media |
1 |
textiles |
1 |
|
cardiovascular |
1 |
median |
1 |
|
severe |
16 |
| dadd |
1 |
or |
1 |
|
np |
1 |
x |
1 |
|
key |
16 |
| photodetection |
1 |
tissues |
1 |
|
lymphoma |
1 |
possible |
1 |
|
e |
16 |
| microenvironment |
1 |
practice |
1 |
|
of |
1 |
reflux |
1 |
|
samples |
16 |
| compounds |
1 |
neuropathies |
1 |
|
compatible |
1 |
defined |
1 |
|
evidence |
16 |
| pioneering |
1 |
flow |
1 |
|
generalizable |
1 |
impacts |
1 |
|
free |
16 |
| impedance |
1 |
strategy |
1 |
|
lccn |
1 |
investigating |
1 |
|
binding |
16 |
| 5244 |
1 |
unambiguously |
1 |
|
b |
1 |
affinity |
1 |
|
expression |
16 |
| monotherapy |
1 |
several |
1 |
|
here |
1 |
magnetic |
1 |
|
thus |
15 |
| management |
1 |
subgenomes |
1 |
|
benefits |
1 |
all |
1 |
|
like |
15 |
| 6tmp |
1 |
simulations |
1 |
|
miscanthus |
1 |
light |
1 |
|
levels |
15 |
| 01 |
1 |
most |
1 |
|
benefit |
1 |
bodv |
1 |
|
control |
15 |
| assembled |
1 |
nsaids |
1 |
|
viable |
1 |
calibrated |
1 |
|
direct |
15 |
| cccs |
1 |
tests |
1 |
|
ced |
1 |
translatable |
1 |
|
assay |
15 |
| accelerometry |
1 |
laboratory |
1 |
|
unable |
1 |
pertinent |
1 |
|
imaging |
15 |
| delivery |
1 |
assays |
1 |
|
is |
1 |
enrolled |
1 |
|
organic |
15 |
| agricultural |
1 |
rigorously |
1 |
|
moderate |
1 |
25 |
1 |
|
factors |
15 |
| benzyladenine |
1 |
spectra |
1 |
|
prostate |
1 |
newly |
1 |
|
without |
15 |
| basis |
1 |
conclusively |
1 |
|
candidemia |
1 |
thermoelectrics |
1 |
|
vitro |
15 |
| phagocytosis |
1 |
itself |
1 |
|
catalytically |
1 |
higher |
1 |
|
virus |
15 |
| normalization |
1 |
cytology |
1 |
|
carry |
1 |
complications |
1 |
|
10 |
15 |
| although |
1 |
ici |
1 |
|
adenoma |
1 |
hplc |
1 |
|
possible |
15 |
| superconductor |
1 |
gene |
1 |
|
unresectable |
1 |
robust |
1 |
|
applications |
15 |
| evidence |
1 |
fact |
1 |
|
vrl |
1 |
subset |
1 |
|
ct |
15 |
| content |
1 |
water |
1 |
|
incredibly |
1 |
complete |
1 |
|
under |
15 |
| might |
1 |
here |
1 |
|
low |
1 |
vocs |
1 |
|
o |
15 |
| macromolecules |
1 |
independently |
1 |
|
gvhd |
1 |
tb |
1 |
|
state |
14 |
| treatment |
1 |
binding |
1 |
|
using |
1 |
some |
1 |
|
selective |
14 |
| gallic |
1 |
verification |
1 |
|
abundance |
1 |
efficient |
1 |
|
promising |
14 |
| dye |
1 |
991 |
1 |
|
diagnosis |
1 |
using |
1 |
|
15 |
14 |
| 51 |
1 |
efs |
1 |
|
based |
1 |
superior |
1 |
|
probable |
14 |
| npa |
1 |
crystals |
1 |
|
almond |
1 |
toward |
1 |
|
three |
14 |
| oce |
1 |
emb |
1 |
|
sarcoma |
1 |
from |
1 |
|
if |
14 |
| phenotype |
1 |
antibody |
1 |
|
statistically |
1 |
cell |
1 |
|
tumor |
14 |
| pericytes |
1 |
three |
1 |
|
cardiomyopathy |
1 |
under |
1 |
|
2019 |
14 |
| arcs |
1 |
fgg |
1 |
|
deep |
1 |
paleo |
1 |
|
all |
14 |
| implementation |
1 |
technique |
1 |
|
anti |
1 |
ion |
1 |
|
available |
14 |
| given |
1 |
sugar |
1 |
|
these |
1 |
approaches |
1 |
|
structure |
14 |
| unable |
1 |
theoretically |
1 |
|
through |
1 |
whenever |
1 |
|
so |
14 |
| cyclobutanones |
1 |
hypx |
1 |
|
capable |
1 |
especially |
1 |
|
18 |
14 |
| representing |
1 |
surveys |
1 |
|
inconclusive |
1 |
unrealizable |
1 |
|
related |
14 |
| discussed |
1 |
fetuses |
1 |
|
e |
1 |
affordable |
1 |
|
cellular |
14 |
| 83 |
1 |
drug |
1 |
|
relatively |
1 |
multivariate |
1 |
|
elusive |
14 |
| chip |
1 |
dark |
1 |
|
better |
1 |
state |
1 |
|
co |
14 |
| synthesis |
1 |
status |
1 |
|
type |
1 |
subject |
1 |
|
material |
14 |
| interest |
1 |
cdt |
1 |
|
aortic |
1 |
men |
1 |
|
rna |
14 |
| correction |
1 |
deltad |
1 |
|
pcp |
1 |
changes |
1 |
|
structural |
13 |
| bond |
1 |
explore |
1 |
|
true |
1 |
three |
1 |
|
sensitive |
13 |
| metals |
1 |
organocatalysis |
1 |
|
ct1 |
1 |
role |
1 |
|
successful |
13 |
| stenosis |
1 |
dissection |
1 |
|
repeatedly |
1 |
not |
1 |
|
inhibition |
13 |
| metastatic |
1 |
eventually |
1 |
|
fit |
1 |
adenocarcinoma |
1 |
|
several |
13 |
| distinction |
1 |
metrics |
1 |
|
sars |
1 |
safe1 |
1 |
|
current |
13 |
| does |
1 |
electrodialysis |
1 |
|
52 |
1 |
versatility |
1 |
|
genomic |
13 |
| dearth |
1 |
assembly |
1 |
|
tractable |
1 |
competent |
1 |
|
long |
13 |
| factors |
1 |
investment |
1 |
|
adenocarcinoma |
1 |
entanglement |
1 |
|
presence |
13 |
| gene |
1 |
cerevisiae |
1 |
|
separately |
1 |
genuine |
1 |
|
dna |
13 |
| batteries |
1 |
esterase |
1 |
|
coding |
1 |
locally |
1 |
|
transfer |
13 |
| wastes |
1 |
31 |
1 |
|
mpnst |
1 |
anti |
1 |
|
drugs |
13 |
| obtained |
1 |
had |
1 |
|
ground |
1 |
resistant |
1 |
|
positive |
13 |
| legal |
1 |
flowers |
1 |
|
mmp |
1 |
case |
1 |
|
previously |
13 |
| stoichiometric |
1 |
serologically |
1 |
|
uncomputability |
1 |
prerequisite |
1 |
|
any |
13 |
| contrastingly |
1 |
combines |
1 |
|
pharmacologically |
1 |
reliable |
1 |
|
genetic |
13 |
| pathogenesis |
1 |
interesting |
1 |
|
general |
1 |
its |
1 |
|
large |
13 |
| specific |
1 |
achievement |
1 |
|
ifd |
1 |
robustness |
1 |
|
plasma |
13 |
| globally |
1 |
fining |
1 |
|
cohort |
1 |
grade |
1 |
|
identified |
13 |
| gamma |
1 |
india |
1 |
|
aifr |
1 |
reporter |
1 |
|
diseases |
13 |
| index |
1 |
inhibitor |
1 |
|
mcns |
1 |
mortality |
1 |
|
primary |
13 |
| medt |
1 |
biosensor |
1 |
|
anticancer |
1 |
different |
1 |
|
signaling |
13 |
| chain |
1 |
genes |
1 |
|
n |
1 |
when |
1 |
|
safe |
13 |
| awsem |
1 |
cholesterol |
1 |
|
slower |
1 |
identity |
1 |
|
findings |
13 |
| variants |
1 |
activity |
1 |
|
insufficient |
1 |
wide |
1 |
|
hiv |
13 |
| particles |
1 |
histopathology |
1 |
|
breast |
1 |
complexity |
1 |
|
sars |
13 |
| ultrastructural |
1 |
tissue |
1 |
|
anything |
1 |
target |
1 |
|
cov |
13 |
| dataset |
1 |
site |
1 |
|
oms |
1 |
consistent |
1 |
|
identifying |
13 |
| corpus |
1 |
octabromination |
1 |
|
widely |
1 |
evm |
1 |
|
mediated |
13 |
| selected |
1 |
cytologically |
1 |
|
iri |
1 |
further |
1 |
|
recently |
13 |
| use |
1 |
likely |
1 |
|
accurate |
1 |
iri |
1 |
|
systems |
12 |
| transfer |
1 |
quantitation |
1 |
|
neurocysticercosis |
1 |
predictions |
1 |
|
recipients |
12 |
| whether |
1 |
memory |
1 |
|
potent |
1 |
thereby |
1 |
|
identification |
12 |
| agent |
1 |
long |
1 |
|
patient |
1 |
need |
1 |
|
tools |
12 |
| scheme |
1 |
patient |
1 |
|
whether |
1 |
d |
1 |
|
early |
12 |
| targets |
1 |
ae16w |
1 |
|
independent |
1 |
valid |
1 |
|
approaches |
12 |
| rts |
1 |
accessions |
1 |
|
comparable |
1 |
boson |
1 |
|
better |
12 |
| hydroxyurea |
1 |
techniques |
1 |
|
linear |
1 |
g |
1 |
|
sequencing |
12 |
| modification |
1 |
26 |
1 |
|
applicable |
1 |
161 |
1 |
|
independent |
12 |
| ligands |
1 |
ligand |
1 |
|
without |
1 |
heat |
1 |
|
interaction |
12 |
| zoomit |
1 |
software |
1 |
|
dangerous |
1 |
1 |
1 |
|
stage |
12 |
| antipsychotics |
1 |
agonists |
1 |
|
classes |
1 |
alleviate |
1 |
|
coronavirus |
12 |
| biology |
1 |
samplers |
1 |
|
expression |
1 |
fastmulrfs |
1 |
|
tissue |
12 |
| safety |
1 |
time |
1 |
|
cdi |
1 |
intractable |
1 |
|
active |
12 |
| release |
1 |
analogues |
1 |
|
equal |
1 |
good |
1 |
|
some |
12 |
| memories |
1 |
eight |
1 |
|
caap |
1 |
reduce |
1 |
|
various |
12 |
| teleosts |
1 |
51 |
1 |
|
fabry |
1 |
suited |
1 |
|
system |
12 |
| residue |
1 |
oil |
1 |
|
sub |
1 |
dissection |
1 |
|
energy |
12 |
| describe |
1 |
radiologically |
1 |
|
not |
1 |
predicting |
1 |
|
increase |
12 |
| flr |
1 |
presented |
1 |
|
renal |
1 |
14 |
1 |
|
mechanism |
12 |
| plants |
1 |
models |
1 |
|
systemic |
1 |
both |
1 |
|
biological |
12 |
| br |
1 |
would |
1 |
|
tremendously |
1 |
rcc |
1 |
|
monitoring |
12 |
| contact |
1 |
group |
1 |
|
on |
1 |
significance |
1 |
|
age |
12 |
| graphs |
1 |
sensitization |
1 |
|
inefficient |
1 |
inhibition |
1 |
|
addition |
12 |
| timp3 |
1 |
2 |
1 |
|
relevant |
1 |
presumably |
1 |
|
known |
12 |
| then |
1 |
labels |
1 |
|
entanglement |
1 |
efficiently |
1 |
|
conditions |
12 |
| eno |
1 |
cancer |
1 |
|
robust |
1 |
remarkable |
1 |
|
performed |
12 |
| chnps |
1 |
separation |
1 |
|
unsuitable |
1 |
cov |
1 |
|
information |
12 |
| carbon |
1 |
10 |
1 |
|
disseminated |
1 |
beneficial |
1 |
|
processes |
12 |
| modulation |
1 |
responses |
1 |
|
inactive |
1 |
uniqueness |
1 |
|
higher |
12 |
| classifications |
1 |
odours |
1 |
|
options |
1 |
validity |
1 |
|
limited |
12 |
| metacognition |
1 |
herein |
1 |
|
normal |
1 |
eyes |
1 |
|
underwent |
12 |
| access |
1 |
int |
1 |
|
practical |
1 |
benefits |
1 |
|
groups |
12 |
| true |
1 |
trpv1 |
1 |
|
parents |
1 |
however |
1 |
|
association |
12 |
| diboratabenzenes |
1 |
atm |
1 |
|
ability |
1 |
result |
1 |
|
species |
12 |
| suspected |
1 |
differentiating |
1 |
|
mostly |
1 |
possibility |
1 |
|
induced |
12 |
| proteomic |
1 |
function |
1 |
|
symptomatic |
1 |
positive |
1 |
|
significant |
12 |
| aiming |
1 |
dmri |
1 |
|
betacyanin |
1 |
reliability |
1 |
|
liver |
12 |
| latter |
1 |
currently |
1 |
|
ie |
1 |
impressive |
1 |
|
group |
12 |
| paraspeckles |
1 |
sensor |
1 |
|
metastatic |
1 |
value |
1 |
|
transplant |
12 |
| heart |
1 |
unequivocally |
1 |
|
opportunities |
1 |
numerical |
1 |
|
imi |
12 |
| saed |
1 |
lattices |
1 |
|
refractory |
1 |
crlf2 |
1 |
|
learning |
11 |
| sensors |
1 |
exceptions |
1 |
|
resistant |
1 |
carrying |
1 |
|
effect |
11 |
| clinical |
1 |
pairs |
1 |
|
scalable |
1 |
increased |
1 |
|
suitable |
11 |
| phyllosphere |
1 |
analogue |
1 |
|
extracardiac |
1 |
technologies |
1 |
|
immune |
11 |
| mediated |
1 |
ileocolonoscopies |
1 |
|
laser |
1 |
underwent |
1 |
|
r |
11 |
| proliferation |
1 |
detection |
1 |
|
largely |
1 |
there |
1 |
|
genome |
11 |
| continuous |
1 |
hyd |
1 |
|
much |
1 |
physiological |
1 |
|
because |
11 |
| entities |
1 |
psa |
1 |
|
tretinoin |
1 |
published |
1 |
|
sensitivity |
11 |
| functionality |
1 |
lacks |
1 |
|
requisite |
1 |
great |
1 |
|
review |
11 |
| msi |
1 |
identified |
1 |
|
suggesting |
1 |
fass |
1 |
|
quantum |
11 |
| ev |
1 |
aurkb |
1 |
|
added |
1 |
stabilize |
1 |
|
therapeutics |
11 |
| principles |
1 |
clarithromycin |
1 |
|
|
|
can |
1 |
|
increased |
11 |
| interrogation |
1 |
season |
1 |
|
|
|
affect |
1 |
|
biomarkers |
11 |
| dynamics |
1 |
ph |
1 |
|
|
|
significant |
1 |
|
level |
11 |
| solids |
1 |
mrdti |
1 |
|
|
|
durable |
1 |
|
survival |
11 |
| water |
1 |
frap |
1 |
|
|
|
13 |
1 |
|
strategies |
11 |
| homoeologous |
1 |
being |
1 |
|
|
|
recruited |
1 |
|
major |
11 |
| retroviruses |
1 |
date |
1 |
|
|
|
recovery |
1 |
|
nafld |
11 |
| md |
1 |
although |
1 |
|
|
|
relative |
1 |
|
previous |
11 |
| agents |
1 |
catalyst |
1 |
|
|
|
implant |
1 |
|
simple |
11 |
| tnfalpha |
1 |
skintronics |
1 |
|
|
|
merits |
1 |
|
negative |
11 |
| diazeniumdiolates |
1 |
result |
1 |
|
|
|
formation |
1 |
|
12 |
11 |
| asymptomatic |
1 |
rivaroxaban |
1 |
|
|
|
applicable |
1 |
|
outcomes |
11 |
| advantage |
1 |
gravitropism |
1 |
|
|
|
scalable |
1 |
|
application |
11 |
| analytically |
1 |
infection |
1 |
|
|
|
toxocariasis |
1 |
|
changes |
11 |
| battery |
1 |
questions |
1 |
|
|
|
data |
1 |
|
among |
11 |
| genotyping |
1 |
even |
1 |
|
|
|
learning |
1 |
|
diagnosis |
11 |
| run |
1 |
considering |
1 |
|
|
|
replication |
1 |
|
magnetic |
11 |
| ins |
1 |
|
|
|
|
|
scalability |
1 |
|
particularly |
11 |
| 617 |
1 |
|
|
|
|
|
suitable |
1 |
|
very |
11 |
| homeostasis |
1 |
|
|
|
|
|
wireless |
1 |
|
interactions |
11 |
| sensor |
1 |
|
|
|
|
|
showing |
1 |
|
less |
11 |
| herein |
1 |
|
|
|
|
|
following |
1 |
|
future |
11 |
| toxicity |
1 |
|
|
|
|
|
since |
1 |
|
value |
11 |
| simulated |
1 |
|
|
|
|
|
generally |
1 |
|
health |
11 |
| summary |
1 |
|
|
|
|
|
focusing |
1 |
|
scale |
11 |
| netd |
1 |
|
|
|
|
|
af4 |
1 |
|
technique |
11 |
| machines |
1 |
|
|
|
|
|
cu |
1 |
|
treatments |
11 |
| aso |
1 |
|
|
|
|
|
modified |
1 |
|
accurate |
11 |
| saliva |
1 |
|
|
|
|
|
12 |
1 |
|
blood |
11 |
| transplant |
1 |
|
|
|
|
|
efficacious |
1 |
|
proposed |
11 |
| pathway |
1 |
|
|
|
|
|
daunting |
1 |
|
experiments |
11 |
| readout |
1 |
|
|
|
|
|
aspergillus |
1 |
|
production |
11 |
| aavs |
1 |
|
|
|
|
|
high |
1 |
|
significantly |
10 |
| adults |
1 |
|
|
|
|
|
could |
1 |
|
furthermore |
10 |
| mutations |
1 |
|
|
|
|
|
characterize |
1 |
|
resistance |
10 |
| characterized |
1 |
|
|
|
|
|
diseases |
1 |
|
likely |
10 |
| mechanotransduction |
1 |
|
|
|
|
|
play |
1 |
|
studied |
10 |
| 1 |
1 |
|
|
|
|
|
vasculitis |
1 |
|
culture |
10 |
| ecl |
1 |
|
|
|
|
|
exposure |
1 |
|
fully |
10 |
| 78 |
1 |
|
|
|
|
|
product |
1 |
|
death |
10 |
| epidermidis |
1 |
|
|
|
|
|
fundamental |
1 |
|
31 |
10 |
| inhibition |
1 |
|
|
|
|
|
understanding |
1 |
|
carbon |
10 |
| interact |
1 |
|
|
|
|
|
pilot |
1 |
|
robust |
10 |
| tlr9 |
1 |
|
|
|
|
|
attractive |
1 |
|
beneficial |
10 |
| sampling |
1 |
|
|
|
|
|
approved |
1 |
|
antibodies |
10 |
| chromophores |
1 |
|
|
|
|
|
mechanistic |
1 |
|
even |
10 |
| tap |
1 |
|
|
|
|
|
predict |
1 |
|
molecules |
10 |
| while |
1 |
|
|
|
|
|
contribute |
1 |
|
techniques |
10 |
| questionnaire |
1 |
|
|
|
|
|
pivotal |
1 |
|
up |
10 |
| domain |
1 |
|
|
|
|
|
quasi |
1 |
|
caused |
10 |
| recurrent |
1 |
|
|
|
|
|
contribution |
1 |
|
rate |
10 |
| metabolites |
1 |
|
|
|
|
|
histoplasmosis |
1 |
|
few |
10 |
| developing |
1 |
|
|
|
|
|
rule |
1 |
|
traditional |
10 |
| pulp |
1 |
|
|
|
|
|
serve |
1 |
|
important |
10 |
| mirnas |
1 |
|
|
|
|
|
multivalent |
1 |
|
design |
10 |
| regression |
1 |
|
|
|
|
|
such |
1 |
|
phase |
10 |
| observation |
1 |
|
|
|
|
|
should |
1 |
|
recent |
10 |
| spheroids |
1 |
|
|
|
|
|
relationship |
1 |
|
electron |
10 |
| formalism |
1 |
|
|
|
|
|
accurate |
1 |
|
ms |
10 |
| antigens |
1 |
|
|
|
|
|
unsuccessful |
1 |
|
proteins |
10 |
| deployed |
1 |
|
|
|
|
|
obtaining |
1 |
|
show |
10 |
| question |
1 |
|
|
|
|
|
these |
1 |
|
genes |
10 |
| hsa |
1 |
|
|
|
|
|
treatments |
1 |
|
size |
10 |
| theoretically |
1 |
|
|
|
|
|
ensemble |
1 |
|
essential |
10 |
| product |
1 |
|
|
|
|
|
absorption |
1 |
|
quantitative |
10 |
| numerical |
1 |
|
|
|
|
|
negative |
1 |
|
2d |
10 |
| crystallographic |
1 |
|
|
|
|
|
ige |
1 |
|
nash |
10 |
| today |
1 |
|
|
|
|
|
making |
1 |
|
screening |
10 |
| natures |
1 |
|
|
|
|
|
hastalex |
1 |
|
pet |
10 |
| 0 |
1 |
|
|
|
|
|
electrochemical |
1 |
|
similar |
10 |
| som |
1 |
|
|
|
|
|
specificity |
1 |
|
derived |
10 |
| particular |
1 |
|
|
|
|
|
sarcoidosis |
1 |
|
sample |
10 |
| gems |
1 |
|
|
|
|
|
blueberry |
1 |
|
multiple |
10 |
| 23 |
1 |
|
|
|
|
|
fluorescence |
1 |
|
lower |
10 |
| single |
1 |
|
|
|
|
|
that |
1 |
|
vaccine |
10 |
| planets |
1 |
|
|
|
|
|
inaccessible |
1 |
|
metal |
10 |
| isolation |
1 |
|
|
|
|
|
an |
1 |
|
networks |
10 |
| monoclonal |
1 |
|
|
|
|
|
easier |
1 |
|
types |
9 |
| d4ttps |
1 |
|
|
|
|
|
typical |
1 |
|
structures |
9 |
| limits |
1 |
|
|
|
|
|
had |
1 |
|
testing |
9 |
| thrombosis |
1 |
|
|
|
|
|
homogenous |
1 |
|
far |
9 |
| ctg |
1 |
|
|
|
|
|
donor |
1 |
|
ligand |
9 |
| crystals |
1 |
|
|
|
|
|
exceptional |
1 |
|
formation |
9 |
| ad |
1 |
|
|
|
|
|
benefit |
1 |
|
targeted |
9 |
| glucocorticoids |
1 |
|
|
|
|
|
|
|
|
via |
9 |
| behaviors |
1 |
|
|
|
|
|
|
|
|
incidence |
9 |
| fermions |
1 |
|
|
|
|
|
|
|
|
prospective |
9 |
| overlaps |
1 |
|
|
|
|
|
|
|
|
found |
9 |
| reducing |
1 |
|
|
|
|
|
|
|
|
loss |
9 |
| traits |
1 |
|
|
|
|
|
|
|
|
developed |
9 |
| ink |
1 |
|
|
|
|
|
|
|
|
limit |
9 |
| surface |
1 |
|
|
|
|
|
|
|
|
nm |
9 |
| sensitivity |
1 |
|
|
|
|
|
|
|
|
beta |
9 |
| purified |
1 |
|
|
|
|
|
|
|
|
mass |
9 |
| field |
1 |
|
|
|
|
|
|
|
|
rapid |
9 |
| erg |
1 |
|
|
|
|
|
|
|
|
recurrence |
9 |
| gestation |
1 |
|
|
|
|
|
|
|
|
alternative |
9 |
| fertility |
1 |
|
|
|
|
|
|
|
|
care |
9 |
| nucleus |
1 |
|
|
|
|
|
|
|
|
synthesis |
9 |
| deltaf |
1 |
|
|
|
|
|
|
|
|
brain |
9 |
| thiourea |
1 |
|
|
|
|
|
|
|
|
algorithm |
9 |
| risk |
1 |
|
|
|
|
|
|
|
|
field |
9 |
| aortic |
1 |
|
|
|
|
|
|
|
|
50 |
9 |
| environments |
1 |
|
|
|
|
|
|
|
|
acid |
9 |
| consequences |
1 |
|
|
|
|
|
|
|
|
spectroscopy |
9 |
| therapy |
1 |
|
|
|
|
|
|
|
|
provide |
9 |
| relationships |
1 |
|
|
|
|
|
|
|
|
stability |
9 |
| transferability |
1 |
|
|
|
|
|
|
|
|
case |
9 |
| neuropathy |
1 |
|
|
|
|
|
|
|
|
ad |
9 |
| by |
1 |
|
|
|
|
|
|
|
|
therefore |
9 |
| fmutp |
1 |
|
|
|
|
|
|
|
|
inflammatory |
9 |
| diagnosed |
1 |
|
|
|
|
|
|
|
|
critical |
9 |
| solitary |
1 |
|
|
|
|
|
|
|
|
challenge |
9 |
| procentriole |
1 |
|
|
|
|
|
|
|
|
retrospective |
9 |
| lysates |
1 |
|
|
|
|
|
|
|
|
metastatic |
9 |
| such |
1 |
|
|
|
|
|
|
|
|
standard |
9 |
| saccharomyces |
1 |
|
|
|
|
|
|
|
|
good |
9 |
| presented |
1 |
|
|
|
|
|
|
|
|
food |
9 |
| conditions |
1 |
|
|
|
|
|
|
|
|
resolution |
9 |
| antagonists |
1 |
|
|
|
|
|
|
|
|
antibody |
9 |
| defects |
1 |
|
|
|
|
|
|
|
|
evaluation |
9 |
| ai |
1 |
|
|
|
|
|
|
|
|
reliable |
9 |
| technique |
1 |
|
|
|
|
|
|
|
|
events |
9 |
| vein |
1 |
|
|
|
|
|
|
|
|
b |
9 |
| sandwich |
1 |
|
|
|
|
|
|
|
|
finally |
9 |
| reaction |
1 |
|
|
|
|
|
|
|
|
activation |
9 |
| two |
1 |
|
|
|
|
|
|
|
|
wide |
9 |
| likely |
1 |
|
|
|
|
|
|
|
|
general |
9 |
| catalysts |
1 |
|
|
|
|
|
|
|
|
optical |
9 |
| images |
1 |
|
|
|
|
|
|
|
|
14 |
9 |
| ifgem |
1 |
|
|
|
|
|
|
|
|
d |
9 |
| ultrafiltration |
1 |
|
|
|
|
|
|
|
|
antigen |
9 |
| crystalline |
1 |
|
|
|
|
|
|
|
|
made |
8 |
| literature |
1 |
|
|
|
|
|
|
|
|
rates |
8 |
| community |
1 |
|
|
|
|
|
|
|
|
wild |
8 |
| paucity |
1 |
|
|
|
|
|
|
|
|
importance |
8 |
| glycine |
1 |
|
|
|
|
|
|
|
|
population |
8 |
| hybridization |
1 |
|
|
|
|
|
|
|
|
70 |
8 |
| amines |
1 |
|
|
|
|
|
|
|
|
clinically |
8 |
| ct |
1 |
|
|
|
|
|
|
|
|
multi |
8 |
| tumors |
1 |
|
|
|
|
|
|
|
|
showed |
8 |
| biomarkers |
1 |
|
|
|
|
|
|
|
|
transplantation |
8 |
| shutdown |
1 |
|
|
|
|
|
|
|
|
linked |
8 |
| cars |
1 |
|
|
|
|
|
|
|
|
heart |
8 |
| critically |
1 |
|
|
|
|
|
|
|
|
failure |
8 |
| gs |
1 |
|
|
|
|
|
|
|
|
ligands |
8 |
| trapping |
1 |
|
|
|
|
|
|
|
|
defects |
8 |
| experimental |
1 |
|
|
|
|
|
|
|
|
graft |
8 |
| vitro |
1 |
|
|
|
|
|
|
|
|
efforts |
8 |
| coffee |
1 |
|
|
|
|
|
|
|
|
accuracy |
8 |
| trams |
1 |
|
|
|
|
|
|
|
|
parameters |
8 |
| gabac |
1 |
|
|
|
|
|
|
|
|
ii |
8 |
| an |
1 |
|
|
|
|
|
|
|
|
five |
8 |
| absence |
1 |
|
|
|
|
|
|
|
|
variety |
8 |
| science |
1 |
|
|
|
|
|
|
|
|
term |
8 |
| remarkable |
1 |
|
|
|
|
|
|
|
|
reducing |
8 |
| gelatin |
1 |
|
|
|
|
|
|
|
|
post |
8 |
| addition |
1 |
|
|
|
|
|
|
|
|
demonstrate |
8 |
| blockade |
1 |
|
|
|
|
|
|
|
|
i |
8 |
| want |
1 |
|
|
|
|
|
|
|
|
cause |
8 |
| prodrug |
1 |
|
|
|
|
|
|
|
|
concept |
8 |
| lipase |
1 |
|
|
|
|
|
|
|
|
memory |
8 |
| stock |
1 |
|
|
|
|
|
|
|
|
technology |
8 |
| signalling |
1 |
|
|
|
|
|
|
|
|
host |
8 |
| category |
1 |
|
|
|
|
|
|
|
|
demonstrated |
8 |
| individuals |
1 |
|
|
|
|
|
|
|
|
date |
8 |
| manner |
1 |
|
|
|
|
|
|
|
|
improve |
8 |
| genes |
1 |
|
|
|
|
|
|
|
|
cardiac |
8 |
| on |
1 |
|
|
|
|
|
|
|
|
self |
8 |
| articles |
1 |
|
|
|
|
|
|
|
|
inhibitors |
8 |
| its |
1 |
|
|
|
|
|
|
|
|
synthetic |
8 |
| assessment |
1 |
|
|
|
|
|
|
|
|
electrochemical |
8 |
| eventually |
1 |
|
|
|
|
|
|
|
|
management |
8 |
| cavernous |
1 |
|
|
|
|
|
|
|
|
result |
8 |
| classified |
1 |
|
|
|
|
|
|
|
|
chain |
8 |
| t2d |
1 |
|
|
|
|
|
|
|
|
four |
8 |
| egfr |
1 |
|
|
|
|
|
|
|
|
diagnostic |
8 |
| active |
1 |
|
|
|
|
|
|
|
|
technologies |
8 |
| beta |
1 |
|
|
|
|
|
|
|
|
animal |
8 |
| time |
1 |
|
|
|
|
|
|
|
|
reduced |
8 |
| predisposition |
1 |
|
|
|
|
|
|
|
|
chemotherapy |
8 |
| lipid |
1 |
|
|
|
|
|
|
|
|
pathology |
8 |
| organelle |
1 |
|
|
|
|
|
|
|
|
identify |
8 |
| substitution |
1 |
|
|
|
|
|
|
|
|
developing |
8 |
| morphology |
1 |
|
|
|
|
|
|
|
|
form |
8 |
| endonucleases |
1 |
|
|
|
|
|
|
|
|
combination |
8 |
| process |
1 |
|
|
|
|
|
|
|
|
dimensional |
8 |
| mofs |
1 |
|
|
|
|
|
|
|
|
action |
8 |
| hcn |
1 |
|
|
|
|
|
|
|
|
consecutive |
8 |
| atfs |
1 |
|
|
|
|
|
|
|
|
order |
8 |
| repeats |
1 |
|
|
|
|
|
|
|
|
chemical |
8 |
| will |
1 |
|
|
|
|
|
|
|
|
stem |
8 |
| samples |
1 |
|
|
|
|
|
|
|
|
propose |
8 |
| atom |
1 |
|
|
|
|
|
|
|
|
analytical |
8 |
| information |
1 |
|
|
|
|
|
|
|
|
viral |
8 |
| automated |
1 |
|
|
|
|
|
|
|
|
per |
8 |
| noise |
1 |
|
|
|
|
|
|
|
|
benefit |
8 |
| epitope |
1 |
|
|
|
|
|
|
|
|
absence |
8 |
| 43 |
1 |
|
|
|
|
|
|
|
|
ion |
8 |
| accurate |
1 |
|
|
|
|
|
|
|
|
successfully |
8 |
| mice |
1 |
|
|
|
|
|
|
|
|
reactions |
8 |
| recognition |
1 |
|
|
|
|
|
|
|
|
local |
8 |
| quantum |
1 |
|
|
|
|
|
|
|
|
present |
8 |
| determined |
1 |
|
|
|
|
|
|
|
|
natural |
8 |
| one |
1 |
|
|
|
|
|
|
|
|
ph |
8 |
| shiv |
1 |
|
|
|
|
|
|
|
|
excellent |
8 |
| inhibitors |
1 |
|
|
|
|
|
|
|
|
proven |
8 |
| anatomy |
1 |
|
|
|
|
|
|
|
|
across |
8 |
| andean |
1 |
|
|
|
|
|
|
|
|
biopsies |
8 |
| friendly |
1 |
|
|
|
|
|
|
|
|
series |
8 |
| purification |
1 |
|
|
|
|
|
|
|
|
being |
8 |
| metidfyr |
1 |
|
|
|
|
|
|
|
|
oxygen |
8 |
| designed |
1 |
|
|
|
|
|
|
|
|
lipid |
8 |
| ifds |
1 |
|
|
|
|
|
|
|
|
metabolic |
8 |
| difficult |
1 |
|
|
|
|
|
|
|
|
women |
8 |
| poct |
1 |
|
|
|
|
|
|
|
|
immunotherapy |
7 |
| canids |
1 |
|
|
|
|
|
|
|
|
potent |
7 |
| rotaviruses |
1 |
|
|
|
|
|
|
|
|
dynamics |
7 |
| viruses |
1 |
|
|
|
|
|
|
|
|
respectively |
7 |
| microscopy |
1 |
|
|
|
|
|
|
|
|
transition |
7 |
| resolution |
1 |
|
|
|
|
|
|
|
|
device |
7 |
| sulfone |
1 |
|
|
|
|
|
|
|
|
treating |
7 |
| generation |
1 |
|
|
|
|
|
|
|
|
gamma |
7 |
| oxygen |
1 |
|
|
|
|
|
|
|
|
great |
7 |
| existing |
1 |
|
|
|
|
|
|
|
|
reduce |
7 |
| prrs |
1 |
|
|
|
|
|
|
|
|
concentrations |
7 |
| cultivars |
1 |
|
|
|
|
|
|
|
|
peptide |
7 |
| ultrasonography |
1 |
|
|
|
|
|
|
|
|
set |
7 |
| simulation |
1 |
|
|
|
|
|
|
|
|
prediction |
7 |
| cxcr2 |
1 |
|
|
|
|
|
|
|
|
remains |
7 |
| passive |
1 |
|
|
|
|
|
|
|
|
pre |
7 |
| over |
1 |
|
|
|
|
|
|
|
|
months |
7 |
| biocatalysis |
1 |
|
|
|
|
|
|
|
|
mortality |
7 |
| n |
1 |
|
|
|
|
|
|
|
|
products |
7 |
| rr |
1 |
|
|
|
|
|
|
|
|
complexity |
7 |
| us |
1 |
|
|
|
|
|
|
|
|
controlled |
7 |
| modality |
1 |
|
|
|
|
|
|
|
|
real |
7 |
| retention |
1 |
|
|
|
|
|
|
|
|
uv |
7 |
| proteases |
1 |
|
|
|
|
|
|
|
|
13 |
7 |
| successfully |
1 |
|
|
|
|
|
|
|
|
68 |
7 |
| peroxide |
1 |
|
|
|
|
|
|
|
|
surface |
7 |
| support |
1 |
|
|
|
|
|
|
|
|
chemistry |
7 |
| geomedd |
1 |
|
|
|
|
|
|
|
|
increasing |
7 |
| possible |
1 |
|
|
|
|
|
|
|
|
work |
7 |
| strong |
1 |
|
|
|
|
|
|
|
|
need |
7 |
| receptors |
1 |
|
|
|
|
|
|
|
|
out |
7 |
| puk |
1 |
|
|
|
|
|
|
|
|
normal |
7 |
| nanoliposomes |
1 |
|
|
|
|
|
|
|
|
followed |
7 |
| o |
1 |
|
|
|
|
|
|
|
|
applied |
7 |
| decades |
1 |
|
|
|
|
|
|
|
|
inhibitor |
7 |
| different |
1 |
|
|
|
|
|
|
|
|
oral |
7 |
| ageing |
1 |
|
|
|
|
|
|
|
|
specifically |
7 |
| farming |
1 |
|
|
|
|
|
|
|
|
designed |
7 |
| diastereomer |
1 |
|
|
|
|
|
|
|
|
already |
7 |
| here |
1 |
|
|
|
|
|
|
|
|
laboratory |
7 |
| phylogenies |
1 |
|
|
|
|
|
|
|
|
regions |
7 |
| spiking |
1 |
|
|
|
|
|
|
|
|
currently |
7 |
| properties |
1 |
|
|
|
|
|
|
|
|
underlying |
7 |
| attractive |
1 |
|
|
|
|
|
|
|
|
living |
7 |
| swarming |
1 |
|
|
|
|
|
|
|
|
recovery |
7 |
| currently |
1 |
|
|
|
|
|
|
|
|
unique |
7 |
| type |
1 |
|
|
|
|
|
|
|
|
last |
7 |
| kinase |
1 |
|
|
|
|
|
|
|
|
support |
7 |
| interferometer |
1 |
|
|
|
|
|
|
|
|
cost |
7 |
| markers |
1 |
|
|
|
|
|
|
|
|
efficacious |
7 |
| context |
1 |
|
|
|
|
|
|
|
|
mean |
7 |
| mixtures |
1 |
|
|
|
|
|
|
|
|
95 |
7 |
| studied |
1 |
|
|
|
|
|
|
|
|
genetically |
7 |
| ventricular |
1 |
|
|
|
|
|
|
|
|
25 |
7 |
| lncrna |
1 |
|
|
|
|
|
|
|
|
given |
7 |
| ml |
1 |
|
|
|
|
|
|
|
|
characterize |
7 |
| myosin |
1 |
|
|
|
|
|
|
|
|
best |
7 |
| chemotherapy |
1 |
|
|
|
|
|
|
|
|
membrane |
7 |
| venetoclax |
1 |
|
|
|
|
|
|
|
|
bkpyv |
7 |
| eeg |
1 |
|
|
|
|
|
|
|
|
prognostic |
7 |
| optimized |
1 |
|
|
|
|
|
|
|
|
prevent |
7 |
| trpm7 |
1 |
|
|
|
|
|
|
|
|
individual |
7 |
| performed |
1 |
|
|
|
|
|
|
|
|
plant |
7 |
| mab |
1 |
|
|
|
|
|
|
|
|
respiratory |
7 |
| electrochemically |
1 |
|
|
|
|
|
|
|
|
stable |
7 |
| receptor |
1 |
|
|
|
|
|
|
|
|
reported |
7 |
| moreover |
1 |
|
|
|
|
|
|
|
|
develop |
7 |
| phenylpyridine |
1 |
|
|
|
|
|
|
|
|
discovery |
7 |
| never |
1 |
|
|
|
|
|
|
|
|
tumors |
7 |
| fd |
1 |
|
|
|
|
|
|
|
|
men |
7 |
| should |
1 |
|
|
|
|
|
|
|
|
rcc |
7 |
| recently |
1 |
|
|
|
|
|
|
|
|
leading |
7 |
| whose |
1 |
|
|
|
|
|
|
|
|
practice |
7 |
| architecture |
1 |
|
|
|
|
|
|
|
|
predicting |
7 |
| pmtct |
1 |
|
|
|
|
|
|
|
|
since |
7 |
| aneurysm |
1 |
|
|
|
|
|
|
|
|
ml |
7 |
| lioh |
1 |
|
|
|
|
|
|
|
|
molecule |
7 |
| artery |
1 |
|
|
|
|
|
|
|
|
same |
7 |
| organisms |
1 |
|
|
|
|
|
|
|
|
processing |
7 |
| underlie |
1 |
|
|
|
|
|
|
|
|
achieved |
7 |
| furthermore |
1 |
|
|
|
|
|
|
|
|
20 |
7 |
| gd |
1 |
|
|
|
|
|
|
|
|
infections |
7 |
| specifically |
1 |
|
|
|
|
|
|
|
|
providing |
7 |
| gcb |
1 |
|
|
|
|
|
|
|
|
enrolled |
7 |
| epr |
1 |
|
|
|
|
|
|
|
|
combined |
7 |
| equations |
1 |
|
|
|
|
|
|
|
|
setting |
7 |
| slurry |
1 |
|
|
|
|
|
|
|
|
scope |
7 |
| ms |
1 |
|
|
|
|
|
|
|
|
mechanical |
7 |
| transcripts |
1 |
|
|
|
|
|
|
|
|
000 |
7 |
| vaccines |
1 |
|
|
|
|
|
|
|
|
containing |
7 |
| malignancies |
1 |
|
|
|
|
|
|
|
|
measurements |
7 |
| radiotherapy |
1 |
|
|
|
|
|
|
|
|
improved |
7 |
| foxp3 |
1 |
|
|
|
|
|
|
|
|
benefits |
7 |
| collection |
1 |
|
|
|
|
|
|
|
|
generation |
7 |
| sqor |
1 |
|
|
|
|
|
|
|
|
sequence |
7 |
| fusion |
1 |
|
|
|
|
|
|
|
|
her2 |
7 |
| derivatives |
1 |
|
|
|
|
|
|
|
|
peptides |
7 |
| hand |
1 |
|
|
|
|
|
|
|
|
resistant |
7 |
| discoveries |
1 |
|
|
|
|
|
|
|
|
seq |
7 |
| nanoelectrodes |
1 |
|
|
|
|
|
|
|
|
aspergillus |
7 |
| beginning |
1 |
|
|
|
|
|
|
|
|
lung |
7 |
| spim |
1 |
|
|
|
|
|
|
|
|
breast |
6 |
| exception |
1 |
|
|
|
|
|
|
|
|
3d |
6 |
| device |
1 |
|
|
|
|
|
|
|
|
agent |
6 |
| cooling |
1 |
|
|
|
|
|
|
|
|
roles |
6 |
| naive |
1 |
|
|
|
|
|
|
|
|
pneumonia |
6 |
| food |
1 |
|
|
|
|
|
|
|
|
23 |
6 |
| relevance |
1 |
|
|
|
|
|
|
|
|
describe |
6 |
| progression |
1 |
|
|
|
|
|
|
|
|
45 |
6 |
| inhibiting |
1 |
|
|
|
|
|
|
|
|
symptom |
6 |
| hiv |
1 |
|
|
|
|
|
|
|
|
efficiency |
6 |
| data |
1 |
|
|
|
|
|
|
|
|
states |
6 |
| reported |
1 |
|
|
|
|
|
|
|
|
precise |
6 |
| could |
1 |
|
|
|
|
|
|
|
|
atomic |
6 |
| rats |
1 |
|
|
|
|
|
|
|
|
secondary |
6 |
| clinic |
1 |
|
|
|
|
|
|
|
|
renal |
6 |
| se |
1 |
|
|
|
|
|
|
|
|
ir |
6 |
| challenge |
1 |
|
|
|
|
|
|
|
|
yet |
6 |
| explicitly |
1 |
|
|
|
|
|
|
|
|
ratio |
6 |
|
|
|
|
|
|
|
|
|
|
relevant |
6 |
|
|
|
|
|
|
|
|
|
|
life |
6 |
|
|
|
|
|
|
|
|
|
|
exposure |
6 |
|
|
|
|
|
|
|
|
|
|
terms |
6 |
|
|
|
|
|
|
|
|
|
|
lead |
6 |
|
|
|
|
|
|
|
|
|
|
elements |
6 |
|
|
|
|
|
|
|
|
|
|
allows |
6 |
|
|
|
|
|
|
|
|
|
|
defined |
6 |
|
|
|
|
|
|
|
|
|
|
extensive |
6 |
|
|
|
|
|
|
|
|
|
|
consistent |
6 |
|
|
|
|
|
|
|
|
|
|
improving |
6 |
|
|
|
|
|
|
|
|
|
|
concentration |
6 |
|
|
|
|
|
|
|
|
|
|
power |
6 |
|
|
|
|
|
|
|
|
|
|
complete |
6 |
|
|
|
|
|
|
|
|
|
|
days |
6 |
|
|
|
|
|
|
|
|
|
|
recognition |
6 |
|
|
|
|
|
|
|
|
|
|
hazard |
6 |
|
|
|
|
|
|
|
|
|
|
60 |
6 |
|
|
|
|
|
|
|
|
|
|
near |
6 |
|
|
|
|
|
|
|
|
|
|
dependent |
6 |
|
|
|
|
|
|
|
|
|
|
day |
6 |
|
|
|
|
|
|
|
|
|
|
still |
6 |
|
|
|
|
|
|
|
|
|
|
moreover |
6 |
|
|
|
|
|
|
|
|
|
|
superior |
6 |
|
|
|
|
|
|
|
|
|
|
sequences |
6 |
|
|
|
|
|
|
|
|
|
|
release |
6 |
|
|
|
|
|
|
|
|
|
|
alpha |
6 |
|
|
|
|
|
|
|
|
|
|
delivery |
6 |
|
|
|
|
|
|
|
|
|
|
compound |
6 |
|
|
|
|
|
|
|
|
|
|
short |
6 |
|
|
|
|
|
|
|
|
|
|
variants |
6 |
|
|
|
|
|
|
|
|
|
|
suggest |
6 |
|
|
|
|
|
|
|
|
|
|
diverse |
6 |
|
|
|
|
|
|
|
|
|
|
generated |
6 |
|
|
|
|
|
|
|
|
|
|
shown |
6 |
|
|
|
|
|
|
|
|
|
|
individuals |
6 |
|
|
|
|
|
|
|
|
|
|
whereas |
6 |
|
|
|
|
|
|
|
|
|
|
classes |
6 |
|
|
|
|
|
|
|
|
|
|
entanglement |
6 |
|
|
|
|
|
|
|
|
|
|
potentially |
6 |
|
|
|
|
|
|
|
|
|
|
initial |
6 |
|
|
|
|
|
|
|
|
|
|
according |
6 |
|
|
|
|
|
|
|
|
|
|
implementation |
6 |
|
|
|
|
|
|
|
|
|
|
pathways |
6 |
|
|
|
|
|
|
|
|
|
|
11 |
6 |
|
|
|
|
|
|
|
|
|
|
quality |
6 |
|
|
|
|
|
|
|
|
|
|
diagnosed |
6 |
|
|
|
|
|
|
|
|
|
|
global |
6 |
|
|
|
|
|
|
|
|
|
|
safety |
6 |
|
|
|
|
|
|
|
|
|
|
line |
6 |
|
|
|
|
|
|
|
|
|
|
past |
6 |
|
|
|
|
|
|
|
|
|
|
atoms |
6 |
|
|
|
|
|
|
|
|
|
|
selection |
6 |
|
|
|
|
|
|
|
|
|
|
theory |
6 |
|
|
|
|
|
|
|
|
|
|
mice |
6 |
|
|
|
|
|
|
|
|
|
|
conducted |
6 |
|
|
|
|
|
|
|
|
|
|
product |
6 |
|
|
|
|
|
|
|
|
|
|
noninvasive |
6 |
|
|
|
|
|
|
|
|
|
|
pathologically |
6 |
|
|
|
|
|
|
|
|
|
|
gangrenous |
6 |
|
|
|
|
|
|
|
|
|
|
detecting |
6 |
|
|
|
|
|
|
|
|
|
|
driven |
6 |
|
|
|
|
|
|
|
|
|
|
factor |
6 |
|
|
|
|
|
|
|
|
|
|
advances |
6 |
|
|
|
|
|
|
|
|
|
|
copper |
6 |
|
|
|
|
|
|
|
|
|
|
advanced |
6 |
|
|
|
|
|
|
|
|
|
|
children |
6 |
|
|
|
|
|
|
|
|
|
|
medical |
6 |
|
|
|
|
|
|
|
|
|
|
domain |
6 |
|
|
|
|
|
|
|
|
|
|
selectivity |
6 |
|
|
|
|
|
|
|
|
|
|
theoretical |
6 |
|
|
|
|
|
|
|
|
|
|
center |
6 |
|
|
|
|
|
|
|
|
|
|
pathway |
6 |
|
|
|
|
|
|
|
|
|
|
mm |
6 |
|
|
|
|
|
|
|
|
|
|
mutant |
6 |
|
|
|
|
|
|
|
|
|
|
quantification |
6 |
|
|
|
|
|
|
|
|
|
|
throughput |
6 |
|
|
|
|
|
|
|
|
|
|
overexpression |
6 |
|
|
|
|
|
|
|
|
|
|
devices |
6 |
|
|
|
|
|
|
|
|
|
|
transcription |
6 |
|
|
|
|
|
|
|
|
|
|
sensing |
6 |
|
|
|
|
|
|
|
|
|
|
aged |
6 |
|
|
|
|
|
|
|
|
|
|
treated |
6 |
|
|
|
|
|
|
|
|
|
|
retrospectively |
6 |
|
|
|
|
|
|
|
|
|
|
enhanced |
6 |
|
|
|
|
|
|
|
|
|
|
plus |
6 |
|
|
|
|
|
|
|
|
|
|
distribution |
6 |
|
|
|
|
|
|
|
|
|
|
anti |
6 |
|
|
|
|
|
|
|
|
|
|
agents |
6 |
|
|
|
|
|
|
|
|
|
|
assays |
6 |
|
|
|
|
|
|
|
|
|
|
effectiveness |
6 |
|
|
|
|
|
|
|
|
|
|
widely |
6 |
|
|
|
|
|
|
|
|
|
|
status |
6 |
|
|
|
|
|
|
|
|
|
|
six |
6 |
|
|
|
|
|
|
|
|
|
|
yields |
6 |
|
|
|
|
|
|
|
|
|
|
laser |
6 |
|
|
|
|
|
|
|
|
|
|
cu |
6 |
|
|
|
|
|
|
|
|
|
|
aortic |
6 |
|
|
|
|
|
|
|
|
|
|
dissection |
6 |
|
|
|
|
|
|
|
|
|
|
reactivity |
5 |
|
|
|
|
|
|
|
|
|
|
bpar |
5 |
|
|
|
|
|
|
|
|
|
|
demonstrating |
5 |
|
|
|
|
|
|
|
|
|
|
newly |
5 |
|
|
|
|
|
|
|
|
|
|
year |
5 |
|
|
|
|
|
|
|
|
|
|
allowed |
5 |
|
|
|
|
|
|
|
|
|
|
able |
5 |
|
|
|
|
|
|
|
|
|
|
specificity |
5 |
|
|
|
|
|
|
|
|
|
|
together |
5 |
|
|
|
|
|
|
|
|
|
|
ventricular |
5 |
|
|
|
|
|
|
|
|
|
|
antibiotics |
5 |
|
|
|
|
|
|
|
|
|
|
noise |
5 |
|
|
|
|
|
|
|
|
|
|
optimized |
5 |
|
|
|
|
|
|
|
|
|
|
common |
5 |
|
|
|
|
|
|
|
|
|
|
believe |
5 |
|
|
|
|
|
|
|
|
|
|
occur |
5 |
|
|
|
|
|
|
|
|
|
|
randomized |
5 |
|
|
|
|
|
|
|
|
|
|
gluten |
5 |
|
|
|
|
|
|
|
|
|
|
profiles |
5 |
|
|
|
|
|
|
|
|
|
|
controls |
5 |
|
|
|
|
|
|
|
|
|
|
analyzed |
5 |
|
|
|
|
|
|
|
|
|
|
assess |
5 |
|
|
|
|
|
|
|
|
|
|
point |
5 |
|
|
|
|
|
|
|
|
|
|
full |
5 |
|
|
|
|
|
|
|
|
|
|
alone |
5 |
|
|
|
|
|
|
|
|
|
|
marker |
5 |
|
|
|
|
|
|
|
|
|
|
severity |
5 |
|
|
|
|
|
|
|
|
|
|
before |
5 |
|
|
|
|
|
|
|
|
|
|
evolution |
5 |
|
|
|
|
|
|
|
|
|
|
migration |
5 |
|
|
|
|
|
|
|
|
|
|
systemic |
5 |
|
|
|
|
|
|
|
|
|
|
interventions |
5 |
|
|
|
|
|
|
|
|
|
|
antiviral |
5 |
|
|
|
|
|
|
|
|
|
|
clinic |
5 |
|
|
|
|
|
|
|
|
|
|
studying |
5 |
|
|
|
|
|
|
|
|
|
|
degradation |
5 |
|
|
|
|
|
|
|
|
|
|
toward |
5 |
|
|
|
|
|
|
|
|
|
|
vis |
5 |
|
|
|
|
|
|
|
|
|
|
aqueous |
5 |
|
|
|
|
|
|
|
|
|
|
viruses |
5 |
|
|
|
|
|
|
|
|
|
|
protocol |
5 |
|
|
|
|
|
|
|
|
|
|
spatial |
5 |
|
|
|
|
|
|
|
|
|
|
published |
5 |
|
|
|
|
|
|
|
|
|
|
feasibility |
5 |
|
|
|
|
|
|
|
|
|
|
access |
5 |
|
|
|
|
|
|
|
|
|
|
existing |
5 |
|
|
|
|
|
|
|
|
|
|
particular |
5 |
|
|
|
|
|
|
|
|
|
|
evaluate |
5 |
|
|
|
|
|
|
|
|
|
|
linear |
5 |
|
|
|
|
|
|
|
|
|
|
clusters |
5 |
|
|
|
|
|
|
|
|
|
|
behavior |
5 |
|
|
|
|
|
|
|
|
|
|
remarkable |
5 |
|
|
|
|
|
|
|
|
|
|
means |
5 |
|
|
|
|
|
|
|
|
|
|
climate |
5 |
|
|
|
|
|
|
|
|
|
|
strains |
5 |
|
|
|
|
|
|
|
|
|
|
importantly |
5 |
|
|
|
|
|
|
|
|
|
|
generate |
5 |
|
|
|
|
|
|
|
|
|
|
detect |
5 |
|
|
|
|
|
|
|
|
|
|
populations |
5 |
|
|
|
|
|
|
|
|
|
|
dynamic |
5 |
|
|
|
|
|
|
|
|
|
|
construction |
5 |
|
|
|
|
|
|
|
|
|
|
lack |
5 |
|
|
|
|
|
|
|
|
|
|
transformation |
5 |
|
|
|
|
|
|
|
|
|
|
usefulness |
5 |
|
|
|
|
|
|
|
|
|
|
experimentally |
5 |
|
|
|
|
|
|
|
|
|
|
existence |
5 |
|
|
|
|
|
|
|
|
|
|
ce |
5 |
|
|
|
|
|
|
|
|
|
|
solid |
5 |
|
|
|
|
|
|
|
|
|
|
chronic |
5 |
|
|
|
|
|
|
|
|
|
|
often |
5 |
|
|
|
|
|
|
|
|
|
|
pharmacological |
5 |
|
|
|
|
|
|
|
|
|
|
way |
5 |
|
|
|
|
|
|
|
|
|
|
healthy |
5 |
|
|
|
|
|
|
|
|
|
|
selected |
5 |
|
|
|
|
|
|
|
|
|
|
analyses |
5 |
|
|
|
|
|
|
|
|
|
|
51 |
5 |
|
|
|
|
|
|
|
|
|
|
routine |
5 |
|
|
|
|
|
|
|
|
|
|
area |
5 |
|
|
|
|
|
|
|
|
|
|
interest |
5 |
|
|
|
|
|
|
|
|
|
|
revealed |
5 |
|
|
|
|
|
|
|
|
|
|
determination |
5 |
|
|
|
|
|
|
|
|
|
|
fruit |
5 |
|
|
|
|
|
|
|
|
|
|
modified |
5 |
|
|
|
|
|
|
|
|
|
|
total |
5 |
|
|
|
|
|
|
|
|
|
|
then |
5 |
|
|
|
|
|
|
|
|
|
|
network |
5 |
|
|
|
|
|
|
|
|
|
|
simulation |
5 |
|
|
|
|
|
|
|
|
|
|
provides |
5 |
|
|
|
|
|
|
|
|
|
|
sufficient |
5 |
|
|
|
|
|
|
|
|
|
|
broad |
5 |
|
|
|
|
|
|
|
|
|
|
complexes |
5 |
|
|
|
|
|
|
|
|
|
|
about |
5 |
|
|
|
|
|
|
|
|
|
|
differences |
5 |
|
|
|
|
|
|
|
|
|
|
replication |
5 |
|
|
|
|
|
|
|
|
|
|
gas |
5 |
|
|
|
|
|
|
|
|
|
|
temperature |
5 |
|
|
|
|
|
|
|
|
|
|
oxidation |
5 |
|
|
|
|
|
|
|
|
|
|
phenotypes |
5 |
|
|
|
|
|
|
|
|
|
|
physiological |
5 |
|
|
|
|
|
|
|
|
|
|
unknown |
5 |
|
|
|
|
|
|
|
|
|
|
native |
5 |
|
|
|
|
|
|
|
|
|
|
cholecystitis |
5 |
|
|
|
|
|
|
|
|
|
|
surgically |
5 |
|
|
|
|
|
|
|
|
|
|
owing |
5 |
|
|
|
|
|
|
|
|
|
|
intervention |
5 |
|
|
|
|
|
|
|
|
|
|
x |
5 |
|
|
|
|
|
|
|
|
|
|
nmdar |
5 |
|
|
|
|
|
|
|
|
|
|
burden |
5 |
|
|
|
|
|
|
|
|
|
|
knowledge |
5 |
|
|
|
|
|
|
|
|
|
|
heartburn |
5 |
|
|
|
|
|
|
|
|
|
|
bacterial |
5 |
|
|
|
|
|
|
|
|
|
|
metabolites |
5 |
|
|
|
|
|
|
|
|
|
|
biology |
5 |
|
|
|
|
|
|
|
|
|
|
adult |
5 |
|
|
|
|
|
|
|
|
|
|
following |
5 |
|
|
|
|
|
|
|
|
|
|
assessing |
5 |
|
|
|
|
|
|
|
|
|
|
allergy |
5 |
|
|
|
|
|
|
|
|
|
|
ga |
5 |
|
|
|
|
|
|
|
|
|
|
mri |
5 |
|
|
|
|
|
|
|
|
|
|
informative |
5 |
|
|
|
|
|
|
|
|
|
|
achieve |
5 |
|
|
|
|
|
|
|
|
|
|
optimization |
5 |
|
|
|
|
|
|
|
|
|
|
diffusion |
5 |
|
|
|
|
|
|
|
|
|
|
correlation |
5 |
|
|
|
|
|
|
|
|
|
|
profile |
5 |
|
|
|
|
|
|
|
|
|
|
uptake |
5 |
|
|
|
|
|
|
|
|
|
|
crucial |
5 |
|
|
|
|
|
|
|
|
|
|
organisms |
5 |
|
|
|
|
|
|
|
|
|
|
humans |
5 |
|
|
|
|
|
|
|
|
|
|
either |
5 |
|
|
|
|
|
|
|
|
|
|
directly |
5 |
|
|
|
|
|
|
|
|
|
|
though |
5 |
|
|
|
|
|
|
|
|
|
|
measures |
5 |
|
|
|
|
|
|
|
|
|
|
variation |
5 |
|
|
|
|
|
|
|
|
|
|
trial |
5 |
|
|
|
|
|
|
|
|
|
|
synthesized |
5 |
|
|
|
|
|
|
|
|
|
|
thereby |
5 |
|
|
|
|
|
|
|
|
|
|
malignancies |
5 |
|
|
|
|
|
|
|
|
|
|
differentiation |
5 |
|
|
|
|
|
|
|
|
|
|
hplc |
5 |
|
|
|
|
|
|
|
|
|
|
sepsis |
5 |
|
|
|
|
|
|
|
|
|
|
tractable |
5 |
|
|
|
|
|
|
|
|
|
|
required |
5 |
|
|
|
|
|
|
|
|
|
|
validated |
5 |
|
|
|
|
|
|
|
|
|
|
catalysts |
5 |
|
|
|
|
|
|
|
|
|
|
catalyst |
5 |
|
|
|
|
|
|
|
|
|
|
artificial |
5 |
|
|
|
|
|
|
|
|
|
|
pathogen |
5 |
|
|
|
|
|
|
|
|
|
|
lipids |
5 |
|
|
|
|
|
|
|
|
|
|
reviewed |
5 |
|
|
|
|
|
|
|
|
|
|
rich |
5 |
|
|
|
|
|
|
|
|
|
|
deep |
5 |
|
|
|
|
|
|
|
|
|
|
pm |
5 |
|
|
|
|
|
|
|
|
|
|
capable |
5 |
|
|
|
|
|
|
|
|
|
|
30 |
5 |
|
|
|
|
|
|
|
|
|
|
conclusion |
5 |
|
|
|
|
|
|
|
|
|
|
enzymes |
5 |
|
|
|
|
|
|
|
|
|
|
relationships |
5 |
|
|
|
|
|
|
|
|
|
|
adenocarcinoma |
5 |
|
|
|
|
|
|
|
|
|
|
relevance |
5 |
|
|
|
|
|
|
|
|
|
|
open |
5 |
|
|
|
|
|
|
|
|
|
|
pd |
5 |
|
|
|
|
|
|
|
|
|
|
mrna |
5 |
|
|
|
|
|
|
|
|
|
|
ci |
5 |
|
|
|
|
|
|
|
|
|
|
progression |
5 |
|
|
|
|
|
|
|
|
|
|
stress |
5 |
|
|
|
|
|
|
|
|
|
|
resonance |
5 |
|
|
|
|
|
|
|
|
|
|
established |
5 |
|
|
|
|
|
|
|
|
|
|
mcfdna |
5 |
|
|
|
|
|
|
|
|
|
|
decades |
5 |
|
|
|
|
|
|
|
|
|
|
2017 |
5 |
|
|
|
|
|
|
|
|
|
|
regulation |
5 |
|
|
|
|
|
|
|
|
|
|
eyes |
5 |
|
|
|
|
|
|
|
|
|
|
test |
5 |
|
|
|
|
|
|
|
|
|
|
coupling |
5 |
|
|
|
|
|
|
|
|
|
|
context |
5 |
|
|
|
|
|
|
|
|
|
|
fibrosis |
5 |
|
|
|
|
|
|
|
|
|
|
reproducible |
5 |
|
|
|
|
|
|
|
|
|
|
shiv |
5 |
|
|
|
|
|
|
|
|
|
|
assessment |
5 |
|
|
|
|
|
|
|
|
|
|
impairment |
5 |
|
|
|
|
|
|
|
|
|
|
oil |
5 |
|
|
|
|
|
|
|
|
|
|
solution |
4 |
|
|
|
|
|
|
|
|
|
|
social |
4 |
|
|
|
|
|
|
|
|
|
|
widespread |
4 |
|
|
|
|
|
|
|
|
|
|
remarkably |
4 |
|
|
|
|
|
|
|
|
|
|
synergistic |
4 |
|
|
|
|
|
|
|
|
|
|
melanoma |
4 |
|
|
|
|
|
|
|
|
|
|
palladium |
4 |
|
|
|
|
|
|
|
|
|
|
catalysis |
4 |
|
|
|
|
|
|
|
|
|
|
confirmed |
4 |
|
|
|
|
|
|
|
|
|
|
ineffective |
4 |
|
|
|
|
|
|
|
|
|
|
needed |
4 |
|
|
|
|
|
|
|
|
|
|
quadruplex |
4 |
|
|
|
|
|
|
|
|
|
|
clear |
4 |
|
|
|
|
|
|
|
|
|
|
discuss |
4 |
|
|
|
|
|
|
|
|
|
|
investigation |
4 |
|
|
|
|
|
|
|
|
|
|
chromatin |
4 |
|
|
|
|
|
|
|
|
|
|
description |
4 |
|
|
|
|
|
|
|
|
|
|
extremely |
4 |
|
|
|
|
|
|
|
|
|
|
kinase |
4 |
|
|
|
|
|
|
|
|
|
|
behaviors |
4 |
|
|
|
|
|
|
|
|
|
|
onset |
4 |
|
|
|
|
|
|
|
|
|
|
47 |
4 |
|
|
|
|
|
|
|
|
|
|
16 |
4 |
|
|
|
|
|
|
|
|
|
|
relative |
4 |
|
|
|
|
|
|
|
|
|
|
amino |
4 |
|
|
|
|
|
|
|
|
|
|
modeling |
4 |
|
|
|
|
|
|
|
|
|
|
achieving |
4 |
|
|
|
|
|
|
|
|
|
|
poor |
4 |
|
|
|
|
|
|
|
|
|
|
areas |
4 |
|
|
|
|
|
|
|
|
|
|
largely |
4 |
|
|
|
|
|
|
|
|
|
|
bladder |
4 |
|
|
|
|
|
|
|
|
|
|
intracellular |
4 |
|
|
|
|
|
|
|
|
|
|
similarity |
4 |
|
|
|
|
|
|
|
|
|
|
cannot |
4 |
|
|
|
|
|
|
|
|
|
|
trials |
4 |
|
|
|
|
|
|
|
|
|
|
prevention |
4 |
|
|
|
|
|
|
|
|
|
|
translation |
4 |
|
|
|
|
|
|
|
|
|
|
decision |
4 |
|
|
|
|
|
|
|
|
|
|
checkpoint |
4 |
|
|
|
|
|
|
|
|
|
|
programmed |
4 |
|
|
|
|
|
|
|
|
|
|
cancers |
4 |
|
|
|
|
|
|
|
|
|
|
semiconductor |
4 |
|
|
|
|
|
|
|
|
|
|
options |
4 |
|
|
|
|
|
|
|
|
|
|
each |
4 |
|
|
|
|
|
|
|
|
|
|
does |
4 |
|
|
|
|
|
|
|
|
|
|
manner |
4 |
|
|
|
|
|
|
|
|
|
|
effectively |
4 |
|
|
|
|
|
|
|
|
|
|
adjusted |
4 |
|
|
|
|
|
|
|
|
|
|
feasible |
4 |
|
|
|
|
|
|
|
|
|
|
option |
4 |
|
|
|
|
|
|
|
|
|
|
hla |
4 |
|
|
|
|
|
|
|
|
|
|
ahr |
4 |
|
|
|
|
|
|
|
|
|
|
71 |
4 |
|
|
|
|
|
|
|
|
|
|
varying |
4 |
|
|
|
|
|
|
|
|
|
|
observed |
4 |
|
|
|
|
|
|
|
|
|
|
asymmetric |
4 |
|
|
|
|
|
|
|
|
|
|
modern |
4 |
|
|
|
|
|
|
|
|
|
|
observational |
4 |
|
|
|
|
|
|
|
|
|
|
source |
4 |
|
|
|
|
|
|
|
|
|
|
image |
4 |
|
|
|
|
|
|
|
|
|
|
spectral |
4 |
|
|
|
|
|
|
|
|
|
|
family |
4 |
|
|
|
|
|
|
|
|
|
|
microenvironment |
4 |
|
|
|
|
|
|
|
|
|
|
contrast |
4 |
|
|
|
|
|
|
|
|
|
|
delivered |
4 |
|
|
|
|
|
|
|
|
|
|
assembled |
4 |
|
|
|
|
|
|
|
|
|
|
utility |
4 |
|
|
|
|
|
|
|
|
|
|
community |
4 |
|
|
|
|
|
|
|
|
|
|
settings |
4 |
|
|
|
|
|
|
|
|
|
|
plants |
4 |
|
|
|
|
|
|
|
|
|
|
fe |
4 |
|
|
|
|
|
|
|
|
|
|
environment |
4 |
|
|
|
|
|
|
|
|
|
|
crispr |
4 |
|
|
|
|
|
|
|
|
|
|
disorder |
4 |
|
|
|
|
|
|
|
|
|
|
whole |
4 |
|
|
|
|
|
|
|
|
|
|
candidates |
4 |
|
|
|
|
|
|
|
|
|
|
revealing |
4 |
|
|
|
|
|
|
|
|
|
|
approved |
4 |
|
|
|
|
|
|
|
|
|
|
architectures |
4 |
|
|
|
|
|
|
|
|
|
|
images |
4 |
|
|
|
|
|
|
|
|
|
|
involved |
4 |
|
|
|
|
|
|
|
|
|
|
observation |
4 |
|
|
|
|
|
|
|
|
|
|
currents |
4 |
|
|
|
|
|
|
|
|
|
|
primarily |
4 |
|
|
|
|
|
|
|
|
|
|
spin |
4 |
|
|
|
|
|
|
|
|
|
|
22 |
4 |
|
|
|
|
|
|
|
|
|
|
content |
4 |
|
|
|
|
|
|
|
|
|
|
blocking |
4 |
|
|
|
|
|
|
|
|
|
|
metastasis |
4 |
|
|
|
|
|
|
|
|
|
|
pc |
4 |
|
|
|
|
|
|
|
|
|
|
red |
4 |
|
|
|
|
|
|
|
|
|
|
17 |
4 |
|
|
|
|
|
|
|
|
|
|
mouse |
4 |
|
|
|
|
|
|
|
|
|
|
swapping |
4 |
|
|
|
|
|
|
|
|
|
|
sets |
4 |
|
|
|
|
|
|
|
|
|
|
metastases |
4 |
|
|
|
|
|
|
|
|
|
|
numerous |
4 |
|
|
|
|
|
|
|
|
|
|
site |
4 |
|
|
|
|
|
|
|
|
|
|
ageing |
4 |
|
|
|
|
|
|
|
|
|
|
versus |
4 |
|
|
|
|
|
|
|
|
|
|
limitations |
4 |
|
|
|
|
|
|
|
|
|
|
hydride |
4 |
|
|
|
|
|
|
|
|
|
|
generating |
4 |
|
|
|
|
|
|
|
|
|
|
distinct |
4 |
|
|
|
|
|
|
|
|
|
|
extent |
4 |
|
|
|
|
|
|
|
|
|
|
intermediate |
4 |
|
|
|
|
|
|
|
|
|
|
decade |
4 |
|
|
|
|
|
|
|
|
|
|
orai1 |
4 |
|
|
|
|
|
|
|
|
|
|
transient |
4 |
|
|
|
|
|
|
|
|
|
|
dnaemia |
4 |
|
|
|
|
|
|
|
|
|
|
corresponding |
4 |
|
|
|
|
|
|
|
|
|
|
indeed |
4 |
|
|
|
|
|
|
|
|
|
|
particles |
4 |
|
|
|
|
|
|
|
|
|
|
suggesting |
4 |
|
|
|
|
|
|
|
|
|
|
uses |
4 |
|
|
|
|
|
|
|
|
|
|
led |
4 |
|
|
|
|
|
|
|
|
|
|
insights |
4 |
|
|
|
|
|
|
|
|
|
|
mild |
4 |
|
|
|
|
|
|
|
|
|
|
antibacterial |
4 |
|
|
|
|
|
|
|
|
|
|
era |
4 |
|
|
|
|
|
|
|
|
|
|
syndrome |
4 |
|
|
|
|
|
|
|
|
|
|
engineering |
4 |
|
|
|
|
|
|
|
|
|
|
index |
4 |
|
|
|
|
|
|
|
|
|
|
complications |
4 |
|
|
|
|
|
|
|
|
|
|
ecological |
4 |
|
|
|
|
|
|
|
|
|
|
making |
4 |
|
|
|
|
|
|
|
|
|
|
predict |
4 |
|
|
|
|
|
|
|
|
|
|
separation |
4 |
|
|
|
|
|
|
|
|
|
|
vs |
4 |
|
|
|
|
|
|
|
|
|
|
residues |
4 |
|
|
|
|
|
|
|
|
|
|
experiment |
4 |
|
|
|
|
|
|
|
|
|
|
regard |
4 |
|
|
|
|
|
|
|
|
|
|
thirty |
4 |
|
|
|
|
|
|
|
|
|
|
predictive |
4 |
|
|
|
|
|
|
|
|
|
|
subset |
4 |
|
|
|
|
|
|
|
|
|
|
growing |
4 |
|
|
|
|
|
|
|
|
|
|
symptoms |
4 |
|
|
|
|
|
|
|
|
|
|
vaccines |
4 |
|
|
|
|
|
|
|
|
|
|
advice |
4 |
|
|
|
|
|
|
|
|
|
|
mucosal |
4 |
|
|
|
|
|
|
|
|
|
|
disorders |
4 |
|
|
|
|
|
|
|
|
|
|
ie |
4 |
|
|
|
|
|
|
|
|
|
|
especially |
4 |
|
|
|
|
|
|
|
|
|
|
considered |
4 |
|
|
|
|
|
|
|
|
|
|
pathogens |
4 |
|
|
|
|
|
|
|
|
|
|
needs |
4 |
|
|
|
|
|
|
|
|
|
|
determine |
4 |
|
|
|
|
|
|
|
|
|
|
calcium |
4 |
|
|
|
|
|
|
|
|
|
|
remained |
4 |
|
|
|
|
|
|
|
|
|
|
64 |
4 |
|
|
|
|
|
|
|
|
|
|
staging |
4 |
|
|
|
|
|
|
|
|
|
|
57 |
4 |
|
|
|
|
|
|
|
|
|
|
loci |
4 |
|
|
|
|
|
|
|
|
|
|
nmr |
4 |
|
|
|
|
|
|
|
|
|
|
second |
4 |
|
|
|
|
|
|
|
|
|
|
rapidly |
4 |
|
|
|
|
|
|
|
|
|
|
investigating |
4 |
|
|
|
|
|
|
|
|
|
|
nature |
4 |
|
|
|
|
|
|
|
|
|
|
evolutionarily |
4 |
|
|
|
|
|
|
|
|
|
|
volume |
4 |
|
|
|
|
|
|
|
|
|
|
dopamine |
4 |
|
|
|
|
|
|
|
|
|
|
mutation |
4 |
|
|
|
|
|
|
|
|
|
|
change |
4 |
|
|
|
|
|
|
|
|
|
|
pain |
4 |
|
|
|
|
|
|
|
|
|
|
nonalcoholic |
4 |
|
|
|
|
|
|
|
|
|
|
late |
4 |
|
|
|
|
|
|
|
|
|
|
intrinsic |
4 |
|
|
|
|
|
|
|
|
|
|
regulatory |
4 |
|
|
|
|
|
|
|
|
|
|
fatty |
4 |
|
|
|
|
|
|
|
|
|
|
diabetic |
4 |
|
|
|
|
|
|
|
|
|
|
leads |
4 |
|
|
|
|
|
|
|
|
|
|
derivatives |
4 |
|
|
|
|
|
|
|
|
|
|
capacity |
4 |
|
|
|
|
|
|
|
|
|
|
additionally |
4 |
|
|
|
|
|
|
|
|
|
|
strain |
4 |
|
|
|
|
|
|
|
|
|
|
f |
4 |
|
|
|
|
|
|
|
|
|
|
tissues |
4 |
|
|
|
|
|
|
|
|
|
|
nps |
4 |
|
|
|
|
|
|
|
|
|
|
tested |
4 |
|
|
|
|
|
|
|
|
|
|
accurately |
4 |
|
|
|
|
|
|
|
|
|
|
microbial |
4 |
|
|
|
|
|
|
|
|
|
|
questions |
4 |
|
|
|
|
|
|
|
|
|
|
assessed |
4 |
|
|
|
|
|
|
|
|
|
|
glucose |
4 |
|
|
|
|
|
|
|
|
|
|
additions |
4 |
|
|
|
|
|
|
|
|
|
|
ev |
4 |
|
|
|
|
|
|
|
|
|
|
adults |
4 |
|
|
|
|
|
|
|
|
|
|
weak |
4 |
|
|
|
|
|
|
|
|
|
|
cd8 |
4 |
|
|
|
|
|
|
|
|
|
|
measurement |
4 |
|
|
|
|
|
|
|
|
|
|
certain |
4 |
|
|
|
|
|
|
|
|
|
|
functions |
4 |
|
|
|
|
|
|
|
|
|
|
detected |
4 |
|
|
|
|
|
|
|
|
|
|
24 |
4 |
|
|
|
|
|
|
|
|
|
|
relationship |
4 |
|
|
|
|
|
|
|
|
|
|
presented |
4 |
|
|
|
|
|
|
|
|
|
|
longitudinal |
4 |
|
|
|
|
|
|
|
|
|
|
gvhd |
4 |
|
|
|
|
|
|
|
|
|
|
serve |
4 |
|
|
|
|
|
|
|
|
|
|
why |
4 |
|
|
|
|
|
|
|
|
|
|
patterns |
4 |
|
|
|
|
|
|
|
|
|
|
oncology |
4 |
|
|
|
|
|
|
|
|
|
|
80 |
4 |
|
|
|
|
|
|
|
|
|
|
receptors |
4 |
|
|
|
|
|
|
|
|
|
|
xtt |
4 |
|
|
|
|
|
|
|
|
|
|
characterized |
4 |
|
|
|
|
|
|
|
|
|
|
pancreatic |
4 |
|
|
|
|
|
|
|
|
|
|
machine |
4 |
|
|
|
|
|
|
|
|
|
|
cooperative |
4 |
|
|
|
|
|
|
|
|
|
|
isolated |
4 |
|
|
|
|
|
|
|
|
|
|
diabetes |
4 |
|
|
|
|
|
|
|
|
|
|
periodontitis |
4 |
|
|
|
|
|
|
|
|
|
|
extension |
4 |
|
|
|
|
|
|
|
|
|
|
maximum |
4 |
|
|
|
|
|
|
|
|
|
|
bulk |
4 |
|
|
|
|
|
|
|
|
|
|
bio |
4 |
|
|
|
|
|
|
|
|
|
|
example |
4 |
|
|
|
|
|
|
|
|
|
|
cognitive |
4 |
|
|
|
|
|
|
|
|
|
|
greatly |
4 |
|
|
|
|
|
|
|
|
|
|
iri |
4 |
|
|
|
|
|
|
|
|
|
|
hydroxyl |
4 |
|
|
|
|
|
|
|
|
|
|
conclude |
4 |
|
|
|
|
|
|
|
|
|
|
represent |
4 |
|
|
|
|
|
|
|
|
|
|
cytotoxic |
4 |
|
|
|
|
|
|
|
|
|
|
transmission |
4 |
|
|
|
|
|
|
|
|
|
|
inflammation |
4 |
|
|
|
|
|
|
|
|
|
|
growth |
4 |
|
|
|
|
|
|
|
|
|
|
ar |
4 |
|
|
|
|
|
|
|
|
|
|
obesity |
4 |
|
|
|
|
|
|
|
|
|
|
67 |
4 |
|
|
|
|
|
|
|
|
|
|
spectrum |
4 |
|
|
|
|
|
|
|
|
|
|
pcr |
4 |
|
|
|
|
|
|
|
|
|
|
january |
4 |
|
|
|
|
|
|
|
|
|
|
december |
4 |
|
|
|
|
|
|
|
|
|
|
mechanistic |
4 |
|
|
|
|
|
|
|
|
|
|
determined |
4 |
|
|
|
|
|
|
|
|
|
|
spectrometry |
4 |
|
|
|
|
|
|
|
|
|
|
atrophy |
4 |
|
|
|
|
|
|
|
|
|
|
k |
4 |
|
|
|
|
|
|
|
|
|
|
folding |
4 |
|
|
|
|
|
|
|
|
|
|
hct |
4 |
|
|
|
|
|
|
|
|
|
|
redox |
4 |
|
|
|
|
|
|
|
|
|
|
mothers |
4 |
|